Shivani Kapur, MD

Hasanali, Z.S., Garfall, A.L., Vogl, D.T., Cohen, A.D., Waxman, A.J., Kapur, S. et al. Mast Cells Enhance Myeloma Engraftment and Promote Bone Destruction in the NSG-hIL6 Patient Derived Xenograft Model , bioRxiv: 2026

Hasanali, Z.S., Garfall, A.L., Vogl, D.T., Cohen, A.D., Waxman, A.J., Susanibar-Adaniya, S.P., Kapur, S., Stadtmauer, E.A., Cipriano, C., Weber, K. and Allman, D. Mast Cells Enhance Myeloma Engraftment and Promote Bone Destruction in the NSG-hIL6 Patient Derived Xenograft Model , bioRxiv, pp.2026-05: 2026

Ho, M., Paruzzo, L., Noll, J.H., Stella, F., Devi, P., Ndeupen, S., Day, Y.A., Chen, G.M., ..., Kapur, S. et al CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy , Nature Medicine: 2026,pp. 1–15

Patel, H., Hubbeling, H., Yu, K., Carpenter, M., LaRiviere, M.J., Plastaras, J.P., ..., Kapur, S. et al Outcomes of radiation integrated with T-cell–engaging bispecific antibodies in relapsed/refractory multiple myeloma' , Blood Advances, 10(4): 2026,1395-99

Paruzzo, L., Luo, T., Ho, M., Patel, H., Stella, F., Vogl, D., Kapur, S., Waxman, A., Porazzi, P., Carturan, A. and Pucillo, M. Consolidative Use of BCMA CAR-T Therapy in Relapsed/Refractory Myeloma—A Retrospective Evaluation. , American Society of Hematology Annual Meeting, Orlando, FL., 25: 2025,92-93.

Patel, H., Hubbeling, H., Yu, K., Carpenter, M., LaRiviere, M., Cohen, A., Kapur, S., Vogl, D., Waxman, A., Stadtmauer, E. and Garfall, A. Outcomes of Radiation Therapy Integrated with T-cell Engaging Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma. , American Society of Hematology Annual Meeting, Orlando, FL., 25: 2025,99

Cohen, A., Susanibar-Adaniya, S., Garfall, A., Vogl, D., Kapur, S., Waxman, A., Zubka, D., Hwang, W.T., Diaczynsky, C., Noll, J. and Ho, M. Phase 2 Study of Cevostamab Consolidation Following BCMA CAR T Cell Therapy: Preliminary Safety and Efficacy Data from the “STEM”(Sequential T Cell-Engagement for Myeloma) Trial. , The American Society of Hematology Annual Meeting, Orlando, FL., 25: 2025,366

Matthew Ho, Luca Paruzzo, Julia Noll, Federico Stella, Sonia Ndeupen, Pooja Devi, Adam Waxman, Shivani Kapur, Fang Chen, Rong Xu, Andrew Huff, Peter Michener, Vanessa Gonzalez, Dan Vogl, David Porter, Aoife Roche, John Everett, Frederic Bushman, Katherine Nathanson, Edward Stadtmauer, Sandra Susanibar-Adaniya, Alfred Garfall, Marco Ruella, Joseph Fraietta, Adam Cohen CD4+ T-Cells Mediate Immune-Related Adverse Events (CirAE) Following BCMA CAR-T Therapy. , Clinical Lymphoma Myeloma and Leukemia., 25(3): 2025,p.S3.

Yu, K., Ho, M., Paruzzo, L., Patel, H., Ruella, M., Kapur, S., Waxman, A., Vogl, D., Cohen, A., Stadtmauer, E. and Garfall, A. Clinical Outcomes after Teclistamab Failure in Relapsed/Refractory Multiple Myeloma. , Clinical Lymphoma, Myeloma and Leukemia, 25: 2025,S64-S65

Paruzzo, L., Eshaghi, K., Ghilardi, G., Doucette, A., Ho, M., Carturan, A., Vogl, D.T., Waxman, A.J., Kapur, S., Fardella, E. and Pucillo, M. Access and outcomes of racial and ethnic minority populations receiving commercial anti-BCMA CART for myeloma. , Blood Immunology & Cellular Therapy, 1(2): 2025,100007